论文部分内容阅读
初发2型糖尿病患者120例,给予口服降糖药物强化治疗,随机分为2组,单纯强化组60例,调脂强化组60例。单纯强化组给予盐酸二甲双胍和(或)阿卡波糖口服,调脂强化组在此基础上联合阿托伐他叮口服。入组前测定患者血压,心率,呼吸,身高,体重,腰围。行标准葡萄糖耐量试验,严格检测肝肾功能,血三脂,胰岛素及其C肽释放水平。治疗2周后复查上述指标,比较治疗效果,计算胰岛素抵抗指数。结果单纯强化组与调脂强化组早期胰岛素分泌水平无明显变化,差异无统计学意义。调脂强化组与单纯强化组相比,调脂强化组甘油三酯明显降低,差异有统计学意义。同时单纯强化组与调脂强化组相比,调脂强化组胰岛素抵抗指数明显改善,有明显统计学差异。结论初发2型糖尿病患者口服药物联合早期调脂治疗对血脂和胰岛素抵抗指数均有明显改善作用。但对早期胰岛素分泌水平无明显改善作用。
120 patients with newly diagnosed type 2 diabetes were given oral hypoglycemic drugs intensive treatment, were randomly divided into two groups, 60 cases of simple strengthening group, 60 cases of lipid-enhancing group. Patients in the simple intensive group were given metformin hydrochloride and / or acarbose orally, and the lipid-fortified group was combined with atorvastatin. Patients before entering the determination of blood pressure, heart rate, breathing, height, weight, waist circumference. Line standard glucose tolerance test, strict detection of liver and kidney function, blood triglyceride, insulin and C peptide release levels. After 2 weeks of treatment, the above indexes were reviewed, and the therapeutic effect was compared to calculate the index of insulin resistance. Results There was no significant difference in early insulin secretion between the simple strengthening group and the lipid-fortified group, the difference was not statistically significant. Lipid-enhancing group compared with the simple strengthening group, the lipid-lowering group of triglycerides was significantly lower, the difference was statistically significant. Meantime, the insulin resistance index of the lipid-fortified group was significantly improved compared with that of the lipid-fortified group. There was a statistically significant difference. Conclusion Oral administration of early-onset type 2 diabetes mellitus combined with early lipid-lowering therapy significantly improved both lipids and insulin resistance index. But no significant improvement in early insulin secretion.